

Stealing a March in the 21st Century: Accelerating Progress in the 100-Year War Against Tobacco Addiction in the United States

Tobacco use in the United States has declined dramatically over the past 50 years, with the prevalence of cigarette smoking falling from about 42% of all adults to less than 20% by 2007. If this rate of decline continues, smoking could be eliminated in the United States by 2047.

Framed in military parlance, we may be halfway through a 100-year war against the leading public health killer of our time. We describe factors that have contributed to progress over the last 50 years and identify policy and other initiatives that can contribute to the elimination of tobacco use in the United States. (*Am J Public Health*. 2009;99:1170–1175. doi:10.2105/AJPH.2008.154559)

Michael C. Fiore, MD, MPH, and Timothy B. Baker, PhD

AMONG THE PUBLIC HEALTH

successes of the 20th century, the decline in tobacco use since the early 1960s has been a historic achievement. As shown in Figure 1, adult smoking in the United States has fallen from a rate of about 42% a half century ago to less than 20% today. Framed in military parlance, we may be at the halfway point in a “100-year war” against tobacco addiction. This framing raises the question of what can be done to shorten this war. In essence, how can we steal a march in the 21st century in the battle against tobacco use and the tobacco industry? We review strategies that have worked thus far and recommend additional steps to further reduce tobacco use and dependence.

Numerous observers have claimed over time that tobacco use has plateaued and that progress against its use has stalled.^{1–3} However, the remarkable decline in rates of tobacco use since the 1960s (Figure 1) belies this claim and underscores the remarkable success of tobacco control efforts to date. A review of smoking prevalence data from the Centers for Disease Control and Prevention shows that adult smoking between 1965 and 2007 declined by an average of about 0.5 percentage point per year (from 42% to 20%; Figure 1), although the actual annual declines have varied over these four decades. Extrapolation of these data reveals that, if this rate of decline continues, smoking will be essentially

eliminated in the United States by about 2047.

Fine-grained analyses of the declines suggest that the overall pattern of decreases was caused by the progressive enactment of new and stronger policies and interventions.^{4–14} Continued innovation of tobacco control efforts and continued attention to tobacco industry tactics (e.g., price discounting, increased marketing of smokeless tobacco products) will be needed to maintain this rate of decline into the future.


What strategies have been most effective in spurring declines in prevalence? There is no doubt that release of information about the health hazards of tobacco drove down use. The surgeon general’s report on the health effects of smoking released in 1964 presaged a burst of prevention and cessation activities.¹⁵ Additionally, the late 1960s demonstrated the power of public health countermarketing,^{16–18} and this was amplified by later public health campaigns.^{4,18–21} Moreover, evidence that secondhand smoke is a significant cause of mortality²² and that tobacco is addictive²³ fostered both the acceptance of clean indoor air policies and the development of evidence-based clinical treatments.^{24–26} Finally, given the cost-sensitive nature of tobacco use, increasing the cost of cigarettes through tobacco excise taxes reliably led to drops in consumption and prevalence.^{5,27–29} Formal modeling analyses suggest that the reductions in prevalence

observed over the last 40 years are a result of such policy changes and interventions as tax increases, clean indoor air laws, advertising restrictions, product labeling laws, youth access laws, mass media campaigns, and increased availability of cessation programs.^{4–14}

POLICIES AND INTERVENTIONS THAT COULD ACCELERATE PROGRESS

Although these successful strategies of the past provide a blueprint for maintaining the current downward pressure on prevalence rates, we believe that additional innovation over the next decade is needed to further accelerate the rate of decline. The strategies that may prove most effective arise from research in a wide array of fields—including public policy, health economics, public health, cessation interventions, prevention, and genetics research—that links the severity of nicotine dependence with age at nicotine exposure.

Age at nicotine exposure warrants special consideration because a large body of converging evidence shows that early exposure is associated with more severe nicotine dependence among adult smokers. Smokers reporting an early onset of smoking (e.g., daily smoking in adolescence) differ from other smokers in that they develop more severe nicotine dependence,^{30–32} smoke more cigarettes a day,^{31,33} and are less likely to quit smoking.^{30,34–39} This



Note. Projections assume that the average percentage point rate of decline per year observed from the 1960s to 2007 will continue. Actual annual rates of decline between the 1960s and 2007 have varied.

FIGURE 1—Smoking prevalence among adults aged 18 years and older: United States, 1965-2007, with projections to 2047.

human research is complemented by animal research showing that compared with initial nicotine exposure during adulthood, exposure during adolescence produces greater effects on the brain,^{40–43} has greater rewarding effects,^{41,44–47} and produces higher levels of self-administration.^{48,49}

Recent data on adult smokers show that a major genetic risk for severe nicotine dependence,^{32,50,51} variations in the nicotinic receptor CHRNA5/A3/B4 gene cluster, will not be expressed unless an individual begins daily smoking prior to age 17 years.³² The implication is that policies and interventions that significantly reduce smoking and nicotine exposure among adolescents will eventually produce a generation of Americans with reduced vulnerability to nicotine dependence. Reducing smoking among youths is an especially important goal since research shows that once an adolescent has progressed to regular, heavy smoking, he or she is unlikely to quit for 20 to 30 years or more.^{52,53} As a result,

every new adolescent smoker today increases smoking prevalence, on average, for several decades.

These considerations lead us to identify several policies and interventions especially worthy of implementation (Box 1).

Tax Increases on Tobacco

Price, the single most effective tobacco use reduction policy currently available, has been underused. From 1965 to 2007, the proportion of the price of an average pack of cigarettes that went to taxes (federal and state) declined from 51.4% to 32.3%, despite significant tax increases by some states.⁵⁴ In 2003, the Subcommittee on Cessation of the Interagency Committee on Smoking and Health proposed a comprehensive tobacco cessation policy program for the United States that included a \$2.00 per pack increase in the cigarette excise tax (with tax parity for noncigarette tobacco products to discourage product switching). The subcommittee estimated that the program would result in 4.7 million new

quitters and a 10% reduction in adult smoking prevalence. Moreover, such a price increase would generate an estimated \$28 billion in new revenue, part of which could be earmarked to fund other aspects of an aggressive campaign to eliminate tobacco use in the United States (including counter-marketing, prevention, cessation, and research components). Importantly, research shows that youths are particularly sensitive

National Media Campaign

to price increases, which have been shown to both promote cessation and prevent initiation of tobacco use among adolescents.^{27,55}

An ongoing, extensive, national paid-media campaign has the potential to further denormalize tobacco use, highlight the dangers of secondhand smoke, discourage youths from initiating tobacco use, and drive tobacco users to use evidence-based cessation treatments.^{56–58} Although such a well-funded, national paid-media effort has not been undertaken, state campaigns and other efforts have documented their effectiveness. For example, California’s comprehensive tobacco control effort, initiated in 1988, resulted in a 39% decline in adult prevalence in 20 years, with prevalence falling from 22.8% in 1988 to 14% in 2007.^{59,60} In contrast, the national rate of tobacco use declined only 30% over that time, from 28.1% in 1988 to 19.8% in 2007.^{61,62} As part of a national campaign, it would be important to include media strategies that affect youths’ attitudes toward both smoking and the tobacco

Policies to Accelerate Progress in the War Against Tobacco

- Enact substantial increases in federal and state tobacco excise taxes
- Ensure access to effective cessation treatments
- Implement a national clean indoor air ordinance
- Execute the systematic elimination of nicotine from tobacco products
- Mandate graphic warning labels on tobacco products
- Fund and execute an aggressive national counter-marketing media campaign
- Enact a comprehensive ban on tobacco advertising, promotion and sponsorship
- Protect adolescents against developing tobacco addiction, particularly during their period of heightened risk
- Enact comprehensive Food and Drug Administration regulation

companies and that appear to reduce their smoking rates.^{4,21,63,64}

Graphic Warning Labels

Graphic warnings have led to significant decreases in tobacco consumption in countries all over the world.^{65–67} Such warnings on cigarette packs have been recommended by the World Health Organization Framework Convention on Tobacco Control.^{68,69} If implemented in the United States, such warnings would provide a low-cost, eminently feasible strategy that has the potential to dramatically boost awareness of risk and increase interest in cessation. In addition to these graphic warnings, cigarette packaging labels that include misleading terms such as “lights” or “mild” should be prohibited.^{70,71}

Advertising, Promotion, and Sponsorship Bans

The Framework Convention on Tobacco Control has recommended a comprehensive ban on tobacco advertising, promotion, and sponsorship.⁷² Such strategies can limit access to protobacco influences. There is evidence that such influences, including the depiction of smoking in movies, result in more favorable perceptions of smoking and contribute to increased tobacco use among youths and young adults.^{73,74} Comprehensive advertising bans reduce tobacco consumption in both developed and developing countries.^{13,14} If implemented in the United States, such bans could powerfully affect tobacco use, particularly among youths and young adults.

National Clean Indoor Air Ordinance

The United States should enact a strong, comprehensive, nationwide ban on indoor smoking, an

approach that has been adopted in many countries throughout the world.⁷⁵ Although more than half of the US population now lives in a state or locality with a comprehensive clean indoor air law,⁷⁵ the absence of a strong national law (without preemptions that limit even stronger state and local ordinances) has limited their effectiveness. There is compelling evidence that such a nationwide ban would not only significantly reduce tobacco prevalence^{25,75–79} but would also dramatically reduce illness and deaths for both smokers and nonsmokers.^{80–84} In fact, smoking bans have been shown to increase quit attempts,^{85–87} decrease levels of consumption,^{75,78,86} decrease smoking among youths,^{25,76,88,89} promote denormalization of smoking,^{85,90} and decrease morbidity and mortality from heart attacks.^{82,83,91–93} Finally, clean indoor air ordinances are popular,^{94,95} and the widespread adoption of state and local bans reflects the substantial public and political acceptance of such policies.⁸⁴

Elimination of Nicotine From Tobacco Products

The gradual elimination of nicotine from commercially available cigarettes, a strategy first proposed by Benowitz and Henningfield in the early 1990s,³⁰ would reduce the risk of nicotine dependence among adolescents by removing the underlying additive substrate for dependence development. At the same time, this policy could assist many adults in overcoming their dependence on tobacco,^{30,96,97} particularly if the potential risk of compensatory smoking was addressed. Such mandated reductions in nicotine content could contribute to another essential strategy for eliminating tobacco use in the

United States—comprehensive regulation of tobacco products and the tobacco industry by the Food and Drug Administration.⁹⁸

Access to Effective Cessation Treatments

A final strategy would involve a greater emphasis on ensuring that all smokers have access to effective treatment interventions. The recently released Public Health Service guideline update, *Treating Tobacco Use and Dependence*,⁹⁹ highlighted vital new information on the clinical treatment of smokers. One important finding was that effective interventions now exist for all types of smokers. For example, there are now interventions that increase quit attempts by smokers who were previously unwilling or unmotivated to quit,^{100,101} providing a treatment option for the 60% to 65% of smokers who do not try to quit each year.^{102,103} The guideline also identified counseling and medication treatments that were especially effective for smokers willing to make a quit attempt, treatments that have been independently endorsed by the Cochrane Collaboration and others.^{104–107} Finally, the 2008 guideline update found that there was now sufficient evidence to recommend certain smoking cessation interventions as effective for adolescent smokers, meaning that this vulnerable population can now benefit from cessation counseling intervention.

DELIVERY OF INTERVENTIONS

At present, most smokers do not enjoy the benefits of such treatment advances. Most smokers unwilling to make a quit attempt

typically receive no intervention, and smokers willing to quit often do not receive the most efficacious interventions.^{99,108,109} This situation is avoidable, because research shows that most smokers visit a health care setting each year.^{110,111} All this underscores the need for enhanced treatment delivery mechanisms, including a greater use of chronic care models, telephone quit lines to deliver optimal smoking interventions to every smoker, and health insurance mandates for the coverage of evidence-based counseling and medication.

It is especially vital that effective treatments reach populations that comprise disproportionate numbers of smokers: individuals with low educational attainment, certain ethnic minorities, and the mentally ill. For instance, mental illnesses such as depression, psychoses, or substance use disorders show smoking prevalence rates that are 2 to 4 times higher than those of the population as a whole.^{112–118} Persons with mental illness or substance abuse disorders constitute 22% of the US population but consume 44% of all cigarettes sold.^{119,120} These populations also bear a disproportionate health and economic burden from tobacco use. Cessation interventions are effective with these populations,⁹⁹ but they too infrequently receive treatment.¹²¹ It is therefore important to fund high-reach intervention delivery systems such as an expanded National Tobacco Quitline Network (1-800-QUIT NOW) that would provide enhanced treatment options, including medication interventions to complement the quit line counseling. The reach of the quit line would be increased by the expanded media campaign that targets underserved populations.^{122–124}

Finally, there is a need for continued research aimed at the development of additional effective interventions: medications including nicotine vaccines,^{125,126} strategies to increase consumer demand for treatment,^{127,128} treatments for those not willing to make a quit attempt at this time, and even more effective counseling interventions.

CONCLUSION

The progress made in reducing tobacco prevalence over the last five decades should in no way temper our commitment to achieving further reductions. On the contrary, we must redouble our efforts because this progress proves the worth and effectiveness of our actions. Nor should progress be misinterpreted to mean that tobacco use is less toxic or that the tobacco companies have been rendered ineffective. Tobacco use remains the leading preventable cause of death and disability in the United States, and the core intent of the tobacco industry is to sow these costs as broadly as possible.

We have reached a tipping point. Progress made over the last 50 years now makes the elimination of tobacco dependence in the United States an achievable goal. Reaching that goal will require innovative policy and clinical approaches that result in an accelerated rate of decline in prevalence. These efforts must enhance previously effective strategies as well as implement novel ones, all while carefully watching the tobacco industry's tactics aimed at undermining our efforts. Given recent research underscoring the relation between early tobacco use and severe lifelong nicotine dependence, it is important to include efforts that significantly reduce tobacco initiation by youths.

Especially promising strategies in this ongoing public health battle include the following: an increased national excise tax on tobacco; aggressive national media campaigns; use of graphic warning labels on cigarette packaging; a comprehensive ban on tobacco advertising, sponsorship, and promotion; an expanded array of effective cessation therapeutics, with greater access to such treatments; a systematic reduction in the nicotine content of commercially available cigarettes; comprehensive Food and Drug Administration regulation of tobacco products and the tobacco industry; and a national ban on indoor smoking. If implemented, the proposed strategies will dramatically reduce adult smoking prevalence while protecting adolescents from becoming dependent on tobacco, thereby stealing a march in the 21st-century war against tobacco use and the tobacco industry. ■

About the Authors

Michael C. Fiore and Timothy B. Baker are with the Center for Tobacco Research and Intervention, School of Medicine and Public Health, University of Wisconsin, Madison. Requests for reprints should be sent to Michael C. Fiore, MD, MPH, Professor of Medicine and Director, University of Wisconsin Center for Tobacco Research and Intervention, 1930 Monroe St, Suite 200, Madison, WI 53711 (e-mail: mcf@tri.medicine.wisc.edu).

This article was accepted January 30, 2009.

Contributors

Both authors developed and wrote the article.

Acknowledgments

This work was supported by a National Institute on Drug Abuse grant to the Center for Tobacco Research and Intervention, University of Wisconsin (grant P50 DA019706).

Over the last three years, M. C. F. has served as an investigator in research studies at the University of Wisconsin that were funded by Pfizer, GlaxoSmithKline, and Nabi Biopharmaceuticals. In 1998, the University of Wisconsin appointed

M. C. F. to a named chair funded by a gift from Glaxo Wellcome. T. B. B. has served as an investigator on research projects sponsored by pharmaceutical companies including Pfizer, Glaxo Wellcome, Sanofi, and Nabi.

References

- Hughes JR. The case for hardening of the target. In: Marcus S, ed. *Those Who Continue to Smoke: Smoking and Tobacco Control Monograph No. 15*. Bethesda, MD: National Institutes of Health, National Cancer Institute; 2003:33–39. NIH publication 03–5370.
- Centers for Disease Control and Prevention. Tobacco use among adults—United States, 2005. *MMWR Morb Mortal Wkly Rep*. 2005;55(42):1145–1148.
- Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 2006. *MMWR Morb Mortal Wkly Rep*. 2007;56(44):1157–1161.
- Farrelly MC, Davis KC, Duke J, Messeri P. Sustaining “truth”: changes in youth tobacco attitudes and smoking intentions after 3 years of a national antismoking campaign. *Health Educ Res*. 2009;24:42–48.
- Wakefield MA, Durkin S, Spittal MJ, et al. Impact of tobacco control policies and mass media campaigns on monthly adult smoking prevalence. *Am J Public Health*. 2008;98(8):1443–1450.
- Levy DT, Romano E, Mumford EA. Recent trends in home and work smoking bans. *Tob Control*. 2004;13(3):258–263.
- Levy DT, Chaloupka F, Gitchell J. The effects of tobacco control policies on smoking rates: a tobacco control scorecard. *J Public Health Manag Pract*. 2004;10(4):338–353.
- Mendez D, Warner KE. Adult cigarette smoking prevalence: declining as expected (not as desired). *Am J Public Health*. 2004;94(2):251–252.
- Shields M. Smoking-prevalence, bans and exposure to second-hand smoke. *Health Rep*. 2007;18(3):67–85.
- Farkas AJ, Gilpin EA, White MM, Pierce JP. Association between household and workplace smoking restrictions and adolescent smoking. *JAMA*. 2000;284(6):717–722.
- McAlister A, Morrison TC, Hu S, et al. Media and community campaign effects on adult tobacco use in Texas. *J Health Commun*. 2004;9(2):95–109.
- Farrelly MC, Davis KC, Haviland ML, Messeri P, Heaton CG. Evidence of a dose–response relationship between “truth” antismoking ads and youth smoking prevalence. *Am J Public Health*. 2005;95(3):425–431.
- Blecher E. The impact of tobacco advertising bans on consumption in developing countries. *J Health Econ*. 2008;27(4):930–942.
- Saffer H, Chaloupka F. The effect of tobacco advertising bans on tobacco consumption. *J Health Econ*. 2000;19(6):1117–1137.
- Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service*. Washington, DC: Dept of Health, Education, and Welfare, Public Health Service; 1964. PHS publication 1103.
- Bailey CJ. From “informed choice” to “social hygiene”: government control of cigarette smoking in the US. *J Am Stud*. 2004;38:41–65.
- Lewit EM, Coate D, Grossman M. *The Effects of Government Regulation on Teenage Smoking*. New York, NY: National Bureau of Economic Research; March 1982.
- Selin H. Mass media and tobacco control. Available at: <http://www.enotes.com/public-health-encyclopedia>. Accessed August 6, 2008.
- Friend K, Levy DT. Reductions in smoking prevalence and cigarette consumption associated with mass-media campaigns. *Health Educ Res*. 2002;17(1):85–98.
- Emery S, Wakefield MA, Terry-McElrath Y, et al. Televised state-sponsored antitobacco advertising and youth smoking beliefs and behavior in the United States, 1999–2000. *Arch Pediatr Adolesc Med*. 2005;159(7):639–645.
- Niederdeppe J, Farrelly MC, Haviland ML. Confirming “truth”: more evidence of a successful tobacco counter-marketing campaign in Florida. *Am J Public Health*. 2004;94(2):255–257.
- The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General*. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2006.
- The Health Consequences of Smoking: A Report of the Surgeon General*. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
- Campaign for Tobacco-Free Kids. Smoke-free laws encourage smokers to quit and discourage youth from starting. Available at: <http://www.tobaccofreekids.org/research/factsheets/pdf/0198.pdf>. Accessed July 23, 2008.
- McMullen KM, Brownson RC, Luke D, Chiqui J. Strength of clean indoor air laws and smoking related outcomes

- in the USA. *Tob Control*. 2005;14(1):43–48.
26. Schroeder SA. Lecture. Shattuck. We can do better—improving the health of the American people. *N Engl J Med*. 2007;357(12):1221–1228.
27. Chaloupka FJ, Cummings KM, Morley CP, Horan JK. Tax, price and cigarette smoking: evidence from the tobacco documents and implications for tobacco company marketing strategies. *Tob Control*. 2002;11(suppl 1):I62–I72.
28. Reed MB, Anderson CM, Vaughn JW, Burns DM. The effect of cigarette price increases on smoking cessation in California. *Prev Sci*. 2008;9(1):47–54.
29. Gallus S, Schiaffino A, La Vecchia C, Townsend J, Fernandez E. Price and cigarette consumption in Europe. *Tob Control*. 2006;15(2):114–119.
30. Benowitz NL, Henningfield JE. Establishing a nicotine threshold for addiction: the implications for tobacco regulation. *N Engl J Med*. 1994;331(2):123–125.
31. Breslau N, Peterson EL. Smoking cessation in young adults: age at initiation of cigarette smoking and other suspected influences. *Am J Public Health*. 1996;86(2):214–220.
32. Taioli E, Wynder EL. Effect of the age at which smoking begins on frequency of smoking in adulthood. *N Engl J Med*. 1991;325(13):968–969.
33. Weiss RB, Baker TB, Cannon DS, et al. A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. *PLoS Genet*. 2008;4(7):e1000125.
34. Lando HA, Thai DT, Murray DM, et al. Age of initiation, smoking patterns, and risk in a population of working adults. *Prev Med*. 1999;29(6 pt 1):590–598.
35. Baker TB, Moffit T, Caspi A, Conti D. The nicotine dependence phenotype: translating theoretical perspectives and extant data into recommendations for genetic mapping. In: Swan GE, ed. *The Nicotine Dependence Phenotype, NCI Monograph No. 22*. Washington, DC: US Dept of Health and Human Services, National Institutes of Health, National Cancer Institute, In press.
36. Chassin L, Presson CC, Sherman SJ, Edwards DA. The natural history of cigarette smoking: predicting young-adult smoking outcomes from adolescent smoking patterns. *Health Psychol*. 1990;9(6):701–716.
37. Cui Y, Wen W, Moriarty CJ, Levine RS. Risk factors and their effects on the dynamic process of smoking relapse among veteran smokers. *Behav Res Ther*. 2006;44(7):967–981.
38. Pisinger C, Vestbo J, Borch-Johnsen K, Jorgensen T. Smoking cessation intervention in a large randomised population-based study. The Inter99 Study. *Prev Med*. 2005;40(3):285–292.
39. Nides MA, Rakos RF, Gonzales D, Murray RP, Tashkin DP, Bjornson-Benson WM. Predictors of initial smoking cessation and relapse through the first 2 years of the Lung Health Study. *J Consult Clin Psychol*. 1995;63(1):60–69.
40. Adriani W, Macri S, Pacifici R, Laviola G. Peculiar vulnerability to nicotine oral self-administration in mice during early adolescence. *Neuropsychopharmacology*. 2002;27(2):212–224.
41. Adriani W, Spijker S, Deroche-Gamonet V, et al. Evidence for enhanced neurobehavioral vulnerability to nicotine during periadolescence in rats. *J Neurosci*. 2003;23(11):4712–4716.
42. Kota D, Martin BR, Damaj MI. Age-dependent differences in nicotine reward and withdrawal in female mice. *Psychopharmacology (Berl)*. 2008;198(2):201–210.
43. Trauth JA, Seidler FJ, Slotkin TA. An animal model of adolescent nicotine exposure: effects on gene expression and macromolecular constituents in rat brain regions. *Brain Res*. 2000;867(1–2):29–39.
44. Trauth JA, Seidler FJ, McCook EC, Slotkin TA. Adolescent nicotine exposure causes persistent upregulation of nicotinic cholinergic receptors in rat brain regions. *Brain Res*. 1999;851(1–2):9–19.
45. Belluzzi JD, Lee AG, Oliff HS, Leslie FM. Age-dependent effects of nicotine on locomotor activity and conditioned place preference in rats. *Psychopharmacology (Berl)*. 2004;174(3):389–395.
46. Belluzzi JD, Wang R, Leslie FM. Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. *Neuropsychopharmacology*. 2005;30(4):705–712.
47. Leslie FM, Loughlin SE, Wang R, Perez L, Lotfipour S, Belluzia JD. Adolescent development of forebrain stimulant responsiveness: insights from animal studies. *Ann N Y Acad Sci*. 2004;1021:148–159.
48. Vastola BJ, Douglas LA, Varlinskaya EI, Spear LP. Nicotine-induced conditioned place preference in adolescent and adult rats. *Physiol Behav*. 2002;77(1):107–114.
49. Levin ED, Lawrence SS, Petro A, et al. Adolescent vs adult-onset nicotine self-administration in male rats: duration of effect and differential nicotinic receptor correlates. *Neurotoxicol Teratol*. 2007;29(4):458–465.
50. Saccone SF, Hinrichs AL, Saccone NL, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. *Hum Mol Genet*. 2007;16(1):36–49.
51. Schlaepfer IR, Hof NR, Collins AC, et al. The CHRNA5/A3/B4 gene cluster variability as an important determinant of early alcohol and tobacco initiation in young adults. *Biol Psychiatry*. 2008;63(11):1039–1046.
52. Chassin L, Presson CC, Pitts SC, Sherman SJ. The natural history of cigarette smoking from adolescence to adulthood in a midwestern community sample: multiple trajectories and their psychosocial correlates. *Health Psychol*. 2000;19(3):223–231.
53. Pierce JP, Gilpin E. How long will today's new adolescent smoker be addicted to cigarettes? *Am J Public Health*. 1996;86(2):253–256.
54. Orzechowski W, Walker RD. The Tax Burden on Tobacco: Historical Compilation. Vol. 37.Q19 Arlington, VA: Orzechowski and Walker; 2003.
55. Pierce JP, Gilmer TP, Lee L, Gilpin EA, de Beyer J, Messer K. Tobacco industry price-subsidizing promotions may overcome the downward pressure of higher prices on initiation of regular smoking. *Health Econ*. 2005;14(10):1061–1071.
56. Fiore MC, Croyle RT, Curry SJ, et al. Preventing 3 million premature deaths and helping 5 million smokers quit: a national action plan for tobacco cessation. *Am J Public Health*. 2004;94(2):205–210.
57. Orleans CT, Arkin EB, Backinger CL, et al. Youth Tobacco Cessation Collaborative and National Blueprint for Action. *Am J Health Behav*. 2003;27(suppl 2):S103–S119.
58. Orleans T, Melvin C, Marx J, Maibach E, Vose KK. National action plan to reduce smoking during pregnancy: the National Partnership to Help Pregnant Smokers Quit. *Nicotine Tob Res*. 2004;6(suppl 2):S269–S277.
59. Mendez D, Warner KE. Setting a challenging yet realistic smoking prevalence target for Healthy People 2020: learning from the California experience. *Am J Public Health*. 2008;98(3):556–559.
60. State Health Facts. California: percent of adults who smoke, 2007. Available at: <http://www.statehealthfacts.org/profileind.jsp?ind=80&cat=2&rgn=6>. Accessed August 7, 2008.
61. Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 1988. *MMWR Morb Mortal Wkly Rep*. 1991;40(44):757–759, 765.
62. Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 2007. *MMWR*
- Morb Mortal Wkly Rep*. 2008;57(45):1221–1226.
63. Bauer UE, Johnson TM, Hopkins RS, Brooks RG. Changes in youth cigarette use and intentions following implementation of a tobacco control program: findings from the Florida Youth Tobacco Survey, 1998–2000. *JAMA*. 2000;284(6):723–728.
64. Siegel M, Biener L. The impact of an antismoking media campaign on progression to established smoking: results of a longitudinal youth study. *Am J Public Health*. 2000;90(3):380–386.
65. Hammond D, Fong GT, Borland R, Cummings KM, McNeill A, Driezen P. Text and graphic warnings on cigarette packages: findings from the International Tobacco Control Four Country Study. *Am J Prev Med*. 2007;32(3):202–209.
66. Thrasher JF, Hammond D, Fong GT, Arillo-Santillan E. Smokers' reactions to cigarette package warnings with graphic imagery and with only text: a comparison between Mexico and Canada. *Salud Publica Mex*. 2007;49(suppl 2):S233–S240.
67. Hammond D, Fong GT, McNeill A, Borland R, Cummings KM. Effectiveness of cigarette warning labels in informing smokers about the risks of smoking: findings from the International Tobacco Control (ITC) Four Country Survey. *Tob Control*. 2006;15(suppl 3):iii19–iii25.
68. Warner KE. The Framework Convention on Tobacco Control: opportunities and issues. *Salud Publica Mex*. 2008;50(suppl 3):S283–S291.
69. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2008: The MPOWER package. Available at: <http://www.who.int/tobacco/mpower/en>. Accessed March 3, 2009.
70. Ashley MJ, Cohen J, Ferrence R. “Light” and “mild” cigarettes: who smokes them? Are they being misled? *Can J Public Health*. 2001;92(6):407–411.
71. Cummings KM, Hyland A, Bansal MA, Giovino GA. What do Marlboro Lights smokers know about low-tar cigarettes? *Nicotine Tob Res*. 2004;6(suppl 3):S323–S332.
72. World Health Organization. WHO Framework Convention on Tobacco Control. 2003. Available at: http://www.who.int/tobacco/framework/WHO_FCTC_english.pdf. Accessed March 3, 2009.
73. Sargent JD, Stoolmiller M, Worth KA, et al. Exposure to smoking depictions in movies: its association with established adolescent smoking. *Arch Pediatr Adolesc Med*. 2007;161(9):849–856.
74. Song AV, Ling PM, Neilands TB, Glantz SA. Smoking in movies and increased smoking among young adults. *Am J Prev Med*. 2007;33(5):396–403.

75. Eriksen MP, Cerak RL. The diffusion and impact of clean indoor air laws. *Annu Rev Public Health*. 2008;29:171–185.
76. Siegel M, Albers AB, Cheng DM, Hamilton WL, Biener L. Local restaurant smoking regulations and the adolescent smoking initiation process: results of a multilevel contextual analysis among Massachusetts youth. *Arch Pediatr Adolesc Med*. 2008;162(5):477–483.
77. Chapman S, Borland R, Scollo M, Brownson RC, Dominello A, Woodward S. The impact of smoke-free workplaces on declining cigarette consumption in Australia and the United States. *Am J Public Health*. 1999;89(7):1018–1023.
78. Farrelly MC, Evans WN, Sfekas AE. The impact of workplace smoking bans: results from a national survey. *Tob Control*. 1999;8(3):272–277.
79. Fong GT, Hyland A, Borland R, et al. Reductions in tobacco smoke pollution and increases in support for smoke-free public places following the implementation of comprehensive smoke-free workplace legislation in the Republic of Ireland: findings from the ITC Ireland/UK Survey. *Tob Control*. 2006;15(suppl 3):iii51–iii58.
80. Centers for Disease Control and Prevention. State smoking restrictions for private-sector worksites, restaurants, and bars—United States, 2004 and 2007. *MMWR Morb Mortal Wkly Rep*. 2008;57(20):549–552.
81. Abrams SM, Mahoney MC, Hyland A, Cummings KM, Davis W, Song L. Early evidence on the effectiveness of clean indoor air legislation in New York State. *Am J Public Health*. 2006;96(2):296–298.
82. Sargent RP, Shepard RM, Glantz SA. Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study. *BMJ*. 2004;328(7446):977–980.
83. Pell JP, Haw S, Cobbe S, et al. Smoke-free legislation and hospitalizations for acute coronary syndrome. *N Engl J Med*. 2008;359(5):482–491.
84. Schmidt CW. A change in the air: smoking bans gain momentum worldwide. *Environ Health Perspect*. 2007;115(8):A412–A415.
85. Albers AB, Siegel M, Cheng DM, Biener L, Rigotti NA. Effect of smoking regulations in local restaurants on smokers' anti-smoking attitudes and quitting behaviours. *Tob Control*. 2007;16(2):101–106.
86. Fichtenberg CM, Glantz SA. Effect of smoke-free workplaces on smoking behaviour: systematic review. *BMJ*. 2002;325(7357):188–194.
87. Shields M. Smoking bans: influence on smoking prevalence. *Health Rep*. 2007;18(3):9–24.
88. Wakefield M, Forster J. Growing evidence for new benefit of clean indoor air laws: reduced adolescent smoking. *Tob Control*. 2005;14(5):292–293.
89. Rainio SU, Rimpela AH. Home smoking bans in Finland and the association with child smoking. *Eur J Public Health*. 2008;18(3):306–311.
90. Albers AB, Siegel M, Cheng DM, Biener L, Rigotti NA. Relation between local restaurant smoking regulations and attitudes towards the prevalence and social acceptability of smoking: a study of youths and adults who eat out predominantly at restaurants in their town. *Tob Control*. 2004;13(4):347–355.
91. Bartecchi C, Alsever RN, Nevin-Woods C, et al. Reduction in the incidence of acute myocardial infarction associated with a citywide smoking ordinance. *Circulation*. 2006;114(14):1490–1496.
92. Cesaroni G, Forastiere F, Agabiti N, Valente P, Zuccaro P, Perucci CA. Effect of the Italian smoking ban on population rates of acute coronary events. *Circulation*. 2008;117(9):1183–1188.
93. Samet JM. Smoking bans prevent heart attacks. *Circulation*. 2006;114(14):1450–1451.
94. Eriksen M, Chaloupka F. The economic impact of clean indoor air laws. *CA Cancer J Clin*. 2007;57(6):367–378.
95. Wakefield M, Roberts L, Owen N. Trends in prevalence and acceptance of workplace smoking bans among indoor workers in South Australia. *Tob Control*. 1996;5(3):205–208.
96. Henningfield JE, Benowitz NL, Slade J, Houston TP, Davis RM, Deitchman SD. Reducing the addictiveness of cigarettes. *Tob Control*. 1998;7(3):281–293.
97. Becker KM, Rose JE, Albino AP. A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation. *Nicotine Tob Res*. 2008;10(7):1139–1148.
98. Brandt AM. FDA regulation of tobacco—pitfalls and possibilities. *N Engl J Med*. 2008;359(5):445–448.
99. Fiore MC, Jaen CR, Baker TB, et al. *Treating Tobacco Use and Dependence: 2008 Update*. Rockville, MD: US Public Health Service; 2008.
100. Williams GC, McGregor HA, Sharp D, et al. Testing a self-determination theory intervention for motivating tobacco cessation: supporting autonomy and competence in a clinical trial. *Health Psychol*. 2006;25(1):91–101.
101. Carpenter MJ, Hughes JR, Solomon LJ, Callas PW. Both smoking reduction with nicotine replacement therapy and motivational advice increase future cessation among smokers unmotivated to quit. *J Consult Clin Psychol*. 2004;72(3):371–381.
102. American Cancer Society. Cigarette smoking. Available at: http://www.cancer.org/docroot/PED/content/PED_10_2X_Cigarette_Smoking.asp. Accessed August 14, 2008.
103. US Public Health Service. Treating tobacco use and dependence: fact sheet. Available at: <http://www.surgeongeneral.gov/tobacco/smokfact.htm>. Accessed August 14, 2008.
104. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. *Cochrane Database Syst Rev*. 2005;(2):CD001292.
105. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. *Cochrane Database Syst Rev*. 2007;(1):CD000031.
106. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. *Cochrane Database Syst Rev*. 2008;(1):CD000146.
107. Zwar N, Richmond R, Borland R, Stillman S, Cunningham M, Litt J. *Smoking Cessation Guidelines for Australian General Practice*. Canberra: Department of Health and Ageing, Commonwealth of Australia; 2004.
108. Browning KK, Ferketich AK, Saltsberry PJ, Wewers ME. Socioeconomic disparity in provider-delivered assistance to quit smoking. *Nicotine Tob Res*. 2008;10(1):55–61.
109. Chase EC, McMenamin SB, Halpin HA. Medicaid provider delivery of the 5A's for smoking cessation counseling. *Nicotine Tob Res*. 2007;9(11):1095–1101.
110. Centers for Disease Control and Prevention. Physician and other health-care professional counseling of smokers to quit—United States, 1991. *MMWR Morb Mortal Wkly Rep*. 1993;42(44):854–857.
111. Drilea SK, Reid BC, Li CH, Hyman JJ, Manski RJ. Dental visits among smoking and nonsmoking US adults in 2000. *Am J Health Behav*. 2005;29(5):462–471.
112. Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. *Am J Addict*. 2005;14(2):106–123.
113. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. *JAMA*. 2000;284(20):2606–2610.
114. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. *Schizophr Res*. 2005;76(2–3):135–157.
115. Vanable PA, Carey MP, Carey KB, Maisto SA. Smoking among psychiatric outpatients: relationship to substance use, diagnosis, and illness severity. *Psychol Addict Behav*. 2003;17(4):259–265.
116. Morris CD, Alexis AA, Turnbull JJ, Dickinson M. Predictors of tobacco use among persons with mental illnesses in a statewide population. *Psychiatr Serv*. 2006;57:1035–1038.
117. Kandel DB, Chen K. Extent of smoking and nicotine dependence in the United States: 1991–1993. *Nicotine Tob Res*. 2000;2(3):263–274.
118. Patton GC, Carlin JB, Coffey C, Wolfe R, Hibbert M, Bowes G. Depression, anxiety, and smoking initiation: a prospective study over 3 years. *Am J Public Health*. 1998;88(10):1518–1522.
119. Kandel DB, Huang FY, Davies M. Comorbidity between patterns of substance use dependence and psychiatric syndromes. *Drug Alcohol Depend*. 2001;64(2):233–241.
120. *Mental Health: A Report of the Surgeon General—Executive Summary*. Rockville, MD: US Dept of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health; 1999.
121. Thorndike AN, Stafford RS, Rigotti NA. US physicians' treatment of smoking in outpatients with psychiatric diagnoses. *Nicotine Tob Res*. 2001;3:85–91.
122. Anderson CM, Zhu SH. Tobacco quitlines: looking back and looking ahead. *Tob Control*. 2007;16(suppl 1):i81–i86.
123. Borland R, Segan CJ. The potential of quitlines to increase smoking cessation. *Drug Alcohol Rev*. 2006;25(1):73–78.
124. Lichtenstein E, Glasgow RE, Lando HA, Ossip-Klein DJ, Boles SM. Telephone counseling for smoking cessation: rationales and meta-analytic review of evidence. *Health Educ Res*. 1996;11(2):243–257.
125. Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. *PLoS ONE*. 2008;3(6):e2547.
126. Wagena EJ, de Vos A, Horwith G, van Schayck CP. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial. *Nicotine Tob Res*. 2008;10(1):213–218.
127. Domenighetti G, Grilli R, Liberati A. Promoting consumers' demand for evidence-based medicine. *Int J Technol Assess Health Care*. 1998;14(1):97–105.
128. Parente ST, Salkever DS, DaVanzo J. The role of consumer knowledge of insurance benefits in the demand for preventive health care among the elderly. *Health Econ*. 2005;14(1):25–38.